ArticleAnalytical chemistry2026
Fast and Scalable Sample Preparation for Integrated Metabolome and Exposome-Wide Association Studies (MWAS/ExWAS).
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Broad coverage exposome- and metabolome-wide association studies rely on advanced instrumentation, typically anchored in liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to investigate exposure-effect associations. Sample preparation for biological fluids is a delicate matter, as it is essential to strike a pragmatic balance between sensitivity, chemical coverage, robustness, and time efficiency to meet the requirements of large-scale epidemiological studies. Here, we established a protein precipitation workflow in a scalable, high-throughput format for human plasma and urine. Different protocols were evaluated utilizing a xenobiotic mixture containing >200 exposure compounds based on extraction recovery, repeatability, and applicability for nontargeted analysis (NTA) and suspect screening. The tested high-throughput options included a protein precipitation workflow in 96-well plates and a phospholipid removal plate. For urine, a dilute-and-shoot approach was additionally tested. The plate-based protein precipitation resulted in superior performance with acceptable extraction recoveries (RE, 60-140%) for >70% of the highly diverse analyte panel in plasma and >80% in urine, and acceptable repeatability with relative standard deviations of <30% for more than 95% of analytes in plasma and 80% in urine. NTA results exhibited only a small number of altered annotated features compared to a tube-based protocol used for benchmarking, while increasing the overall time efficiency by a factor of five. To further test the protocol, it was applied to the NIST plasma standard reference material SRM1950. A total of 22 toxicants were identified and (semi-)quantified, with most concentrations comparable to available reference values. The results demonstrate the suitability of the established protocol for combined MWAS/ExWAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.